Progenics Pharmaceuticals (PGNX) 10-K2012 FY Annual report

Filed: 15 Mar 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abuse, accuracy, added, addressed, adrenal, adult, angelo, Attorney, attrition, Azedra, bone, branded, breakdown, broaden, broadening, broadly, Chair, Chapter, children, constrain, convey, cooperate, Court, curtailment, CytoDyn, debtor, deficient, destroy, dictate, dissection, distinct, District, docetaxel, embodying, emerging, endeavor, enzalutamide, Ernst, escrow, exempt, feasibility, fit, fraud, freely, FUJIFILM, Germany, goodwill, group, halted, Heath, histopathology, imaging, inquiry, Insight, interdependent, intrusion, Janssen, Jazz, Johnson, jr, judicial, kill, line, lovallo, lymph, machinery, main, mandate, McMaster, Medicaid, Medicare, MedImmune, metastatic, MIP, misappropriate, monthly, morale, MTS, multicenter, multicentered, narrower, networked, neuroblastoma, node, Ontario, orphan, OTC, paraganglioma, path, payload, pelvic, personal, petition, pheochromocytoma, possession, post, prednisone, priority, prolonged, proper, ProstaScint, prostectomy, PSA, radiotherapeutic, radiotherapy, rare, reclassified, redemption, reinstated, relapsed, reliance, relinquish, reorganized, reputational, responding, retroactively, RI, scrutiny, secret, secreted, size, soft, Southern, subpoena, talent, Taxpayer, thereon, tissue, unannounced, unattractive, underwritten, unexpectedly, unforeseen, unqualified, unregistered, voluntary, vulnerable, Western, withhold, workforce, Xtandi, Young

Removed: abundantly, accentuated, activate, affiliated, aggregating, aggressive, AlphaVax, arise, blocked, blocking, blood, book, bowel, brain, bringing, brokerage, Canadian, ceased, cellular, central, combat, composition, consumer, cord, dalton, decided, devoted, dispensed, displacing, dysfunction, endure, entering, exclusively, experiencing, Finally, focused, focusing, formed, gastrointestinal, Governance, gut, HCV, hereof, herewith, immunodeficiency, infection, interacting, interlinked, intervention, kinase, leading, listing, located, marketable, mckinney, medicine, MNK, multiplex, newly, occurring, oncogenic, opting, pace, pathway, peripherally, periphery, preceding, President, problem, produce, prophylactic, proportionate, ras, regulator, resistance, restrictive, returned, selectively, setback, signaling, spinal, subsidize, succeed, synthetic, tract, transitioning, trend, Tudor, turning, twenty, uninfected, vaccine, vice, virology

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PGNX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 12.1

Progenics Pharmaceuticals, Inc.

Ratio of (Loss) Earnings to Combined Fixed Charges and Preferred Stock Dividends

(in thousands)

	Years Ended December 31,
	2012			2011		2010			2009			2008
Determination of (loss) earnings:
(Loss) income from operations	$	(35,431	)	$	10,381	$	(69,820	)	$	(30,612	)	$	(44,672	)
Add:
Fixed charges		410			695		709			555			594

(Loss) earnings, as adjusted	$	(35,021	)	$	11,076	$	(69,111	)	$	(30,057	)	$	(44,078	)

Fixed charges:

Estimate of interest within rental expense		410			695		709			555			594

Fixed charges	$	410		$	695	$	709		$	555		$	594

Preferred stock dividends	$	-		$	-	$	-		$	-		$	-

Ratio of (loss) earnings to fixed charges and preferred stock dividends		*			16		*			*			*
Coverage deficiency amount for total fixed charges and preferred stock dividends ⁽¹⁾	$	35,431		$	-	$	69,820		$	30,612		$	44,672

⁽¹⁾

For the years ended 2008 through 2010 and 2012, the Company's coverage ratio is less than one-to-one and it must generate additional earnings of these specified amounts to achieve a coverage ratio of 1:1.